Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning shorts, Do you remember way back on March 4 when Dick Williams had a huge retirement message posted in the news release from Adamis? If you remember correctly it announced he was going to be retiring as of April 15.
Now when you look at the 8K for Denis’s retirement, it says he is going to be retiring effective immediately. As you can imagine a normal retirement would be announced, and a date would be planned and then it would probably be celebrated. The fact that we just had a conference call two days ago and nothing was announced should be confirmation enough that he was asked to retire.… A.k.a. he was Fired by the board.
I agree with you that TEMPOL results will be out any week now… And ZIMHI is well on its way to being profitable. But the fact remains the share price was continuing to decline until this point. Dennis believed in the science, but he didn’t believe in communicating with the shareholders. I think enough heavy hitters finally said enough is enough. It was either Dennis or the entire board of directors at the next annual meeting.… And now we know the outcome.
I had asked again about posting updated financials.
Response:
True...not endorsed. I corrected.
But still looks very good to have Studies conducted by the NIH on a product that you have world rights to. and especially for them to believe it can be a "Potential Home Treatment for COVID"
https://covid19.nih.gov/news-and-stories/tempol-potential-home-treatment-covid-19
I've only been here for a short while, but I can see a little light at the end of the tunnel for IVR.
I think they learned a hard lesson in only investing in Commercial real Estate with the COVID pandemic. But with a relatively small Float and lots of institutional investors, I can see this going back up to at least 1/2 pre-pandemic levels in the coming months. May be longer than we want, but I can see it getting there eventually.
Good News is that they should make a big gain over last quarter, and they never cut the dividends.
Right now I am only at 1000 shares, but plan to buy more at EOY when I sell for Tax losses on a couple other tickers.
Best of Luck!
Definitely give you a "Follow" Shorts!
~Love the playful banter!
Josey, I agree there are others playing in the field.
;however, the others are not getting their products tested by the NIH...and studies published by the NIH...and labeled as "A possible COVID treatment" by the NIH.
I am bullish here, and own more shares than I probably should. I personally think a buy-out is on the horizon with good data. There are just too many BIG PHARMA companies that want in on the exploitation of COVID to make money, and they do not have their own products. So, what better way than with an Antiviral pill made up of a compound that already has a proven safety record.
Again, just my beliefs.
Gap has definitely been filled from the huge Gap Up yesterday.
Hopefully with the AVIR news hitting the streets, those buyers will move over here to another $1 stock and help to lock up the float a little bit.
Sad that it dropped so badly yesterday (I was not expecting it) and early this AM...my hope is that those who were able to buy down to the .40 mark a few months ago are now all sold out and the sellers will begin to dry up and allow this thing to run like it needs to.
Best of luck everyone!
Good News for ADMP...C'mon TEMPOL
AVIR Covid Treatment missed primary endpoints...Now there are 3 (MRC, PFE, ADMP), and we already know MRC is only 50% effective.
TEMPOL backed by the NIH is looking even better.
https://www.nasdaq.com/articles/3-drugmakers-in-focus-after-mercks-positive-covid-19-pill-data-2021-10-04
Wow...that is Crazy!
It's almost like they "Know" a Buy-Out is coming,
and they Just Don't Care?
~Thoughts?
One catalyst down...now we wait for Interim readout from the TEMPOL trial,
and the thing I would expect next would have to be a Buy-out!
Good Luck everyone!
Hey Cougar, That is in fact what was put out by Adamis.
Funny thing is that they PR’d they were being Subpoenaed by Southern District court of NY over the US Compounding business…then subsequently sold both the Human and Animal Portions of the business. I don’t know how they can sell a business that is being actively investigated…but they did.
With the quarterly’s being late, they have until End of November to get current, or risk being delisted. But with Zimhi PDUFA date due by November 12th, and Tempol preliminary data read outs any day now…I think they already have a buy out offer on the table, and they don’t care about the financials as they won’t matter if the company is sold. US Compounding was going to be cash flow positive, and now it’s gone too…I think it’s because what ever company that is buying out ADMP didn’t need or want it. So Adamis offloaded it to the highest bidders.
That’s my two cents anyway…take it for what it’s worth.
Either way, we will know something definite by end of ovember.
Best of luck!
$ADMP Updated Clinical Trials Website
https://www.clinicaltrials.gov/ct2/show/NCT04729595?cond=TEMPOL&draw=2&rank=3
All testing sites are listed now except a POC for Texas.
Looking like a good sign
Best of luck everyone!
This was not posted here either:
https://www.fagronsterile.com/fss-usc
Speculating that ZIMHI may be approved this week...based on how the process went for SYMJEPI. As they say, "History repeats itself".
No matter how it pans out, PDUFA date 12NOV!
Best of luck everyone!
Your looking at ADMS getting bought out.
Not ADMP.
Hopefully you will read about us in the near future though.
~Cheers
I have been looking for .053 for a while now too, but lowered my GTC Sell order yesterday to .045
Sorry guys, I just can't wait any longer. I took my losses, licked my wounds, and will now use the spare powder for other prospect. GL to all that are patiently waiting. I hope it happens!
Looks like someone just started a pretty big position…
That 250K block looked pretty good!
Hope we get some great interim read outs in a couple weeks.
That and some financials…and this thing could really get going.
SANOFI has bought two small US Biopharmas in the past two months...and they are looking to get into the COVID-19 race as well...
Hmmmmmm.....could ADAMIS be a target too?
France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 bln deal
I too am a little baffled about the PPS at the moment. Seems that anticipation of the Trial a few weeks ago got a bump to $1.22, but actual news can't even get that?
~ Maybe company will provide some 21/28 day readouts to get a little more excitement. If it is as good as NIH would like us to believe, an Emergency Use Order will be right around the corner.
Seems that the lack of the past two quarter's financials may have more of an effect than anyone realized?
Need an analyst to do an upgrade recommendation? Last one was over 15 months ago. The company is well under the radar...and could use the publicity.
B. Riley last update: July 23, 2019
Raymond James last update: November 26, 2019
Maximum last update: May 13, 2020
Anyone know how to contact an analyst to recommend an article? There are many catalysts upcoming to write about and I could only imagine it will be an upgrade to "Outperform"...or at least "Buy".
"First Patient Dosed"
Finally...the long wait is over!
Good Luck everyone...Hold onto you seats!
More Good News...
I see Monroe, NC has just added their study site.
Dr. Awawu Igbinadolor
Monroe Biomedical Research
Contact: Krista Gross
krista.gross@monroeresearch.com
(704) 283-7359
Sure hoping for a news release soon that first patient was dosed?
Can someone fill my $10 sell orders?
That's Great...
Now they need to update the Clinical Trials page and add a few more trial sites. Only one mentioned is Doral in Hialeah, FL.
Then maybe make some announcements that a First Patient was dosed?
So, continuing to coil up, and hopefully soon will spring upwards!
~Good Luck Longs...been waiting for a very long time for good things.
Could 2021 really be "The Year"?
Don't be too quick to jump the Gun.
Site says recruiting, but Doral Medical Research is only a research facility...which may be part of the CRO.
Until they say "First Dose"...or "Trial Underway", I would be cautious.
As of yet, I hadn't seen any sites selected. Typically there should be at least 3 or 4 across a few states to show diversity.
https://www.dnb.com/business-directory/company-profiles.doral_medical_research_llc.130338b28242789487a976f1f289c4ca.html
Great that they are updating the Clinical Trials website...but nothing on the trial yet.
#Still Waiting
Morning Roll,
I can agree that there are several things the Company doesn't have control over such as PDFUA dates and whether or not the FDA approves or denies new drugs.
...but not communicating is truly a company problem.
ADMP knows when they are going to meet or miss reported milestones. specifically dates that they release. What they do need to do is provide guidance and support to shareholders that they have valid reasons for hold ups.(Which may/may not be within their control).
Trials can be completed with the 45M they raised in the last offering. Grant monies for said trials will still be paid as long as they are properly applied for.
Did the company say anything about the 7.9M they paid to Nephron on May 13th after three years in court?
Did they say anything about having to refile quarterly's for the past year because the "Misapplication of valuation principals" in regards to warrants issued to purchase stock?
Have they provided any info to shareholder in regards to how they plan to regain compliance? Or have they told shareholders that they have provided the SEC a plan to regain compliance?
Yes...I am a long, but I am frustrated with the company's lack of communication!
They were great at communicating how important it was to save their butts on the re-election, but not so good at communicating anything else.
Another "Proposed Date" has come and gone again...and nothing from the company?
Seems that the communication problems that have plagued this company for the past 5+ years that I have been here are still happening. Typically companies learn from their mistakes, but apparently that is not the case with ADMP?
Now with another Quarterly report being missed...and nothing from the company, really makes you wonder what is going on behind the scenes?
If there is in fact a buy-out pending Zimhi FDA Approval, wouldn't that be a material event that would need to be shared with the stockholders?
If we have until November to regain NASDAQ compliance...and November is also when Zimhi FDA Approval is expected...is the company really just kicking the proverbial can down the road for financials and putting all the eggs in the "Buy-Out" basket?
I received no less than 5 letters from the company asking me to disregard Hammann's proposals regarding the reelection of the board of directors...but can't get a single letter to explain financials, or a single letter to explain the delay in starting Tempol trials?
Am I the only frustrated Long here?
Are we there yet?
Unfortunately, they already announced they were selling the US Compounding business, So....not much action.
Real news would be to announce they are about to start the COVID trial seeing as Clinicaltrials.GOV now shows a start date of August 25th.
Just a PR stating first patient dosing will begin ..... to treat COVID in line with NIH research, and this thing should start rolling.
Then another PR when the first patient is in fact dosed.
Then interim readouts.
Then Last patient dosed.
Then should be about time for FDA to approve Zimhi.
And of course.....at any time.....they could file the darned Quarterly, and get back in compliance.
Purely Speculation here...3rd time's the charm for ADMP
When SYMJEPI went to the FDA for Approval...for the 3rd iteration, it was submitted on January 19, 2017: Ahead of the 6-month PDUFA Date, FDA approved on June 15, 2017. (Just under 5 Months)
I see a similar pattern going on with ZIMHI...submitted for FDA approval on 3rd iteration on May 17, 2021: PDUFA Date November 15th?....FDA may approve by October 13, 2021. (Again, just under 5 months)
One can only hope it is sooner, but my speculation is by mid October at the latest.
I just love that updates are being made, and that plugs are not being pulled.
After having been here for a few years, I have been excited many times only to be let down later. But this time it finally feels different.
The trial may have been modified based on CRO recommendation, or based on the application requirements to receive grant monies. Having written proposals in the past for a DOJ grant. I know they (grant applications) can be very specific on their requirements to qualify.
Seeing the updates on the clinical trials website only reinforces that they are proceeding as planned…15 days till the middle of the quarter.
Either way, something big is still happening, and the PPS and volume are picking up accordingly.
Agreed…I dont see this making it to November before the FDA makes a decision. Especially with the record number of overdoses over the past year…mostly related to fentanyl.
Could be any day now. I too check the FDA website daily.
Don’t quote me…but maybe 3rd time will be the charm!
Wasn’t SYMJEPI approved on the 3rd attempt on a very similar pattern?
A CRO will be running the trial, but ADMP is still calling the shots and is overall in charge. ADMP picks the primary and secondary endpoints as well as gives blessings to any “recommendations” that the CRO may come up with based on their experience. Yes, it does keep ADMP from screwing things up, or from letting ADMP manipulate the statistics to meet their primary and/or secondary endpoints…but make no mistake, ADMP is the sponsor and is calling the shots. Having a non-biased CRO doing the work is a huge benefit as is having the independent Data Safety Monitoring Board. As the DSMB will keep ADMP from crossing any unethical or safety barriers while they try to meet their endpoints.
What the best part is about all of this is ….most of the legwork was already completed by the National Institute of Health. All ADMP has to do is prove the science that was already demonstrated by the NIH.
Should be a “No-Brainer”!
Goooooooo CRO, Gooooooooo ADMP!
That’s Great! I just checked the Clinical trials site this morning and it said last update was February 21st.
Must mean the trial is starting soon, so Dr. Moss updated the site.
Let’s Gooooooo ADMP!!!
One can only hope!
Gonna be a big 2nd Half of 2021 for ADMP!
Well...The Exact Middle of the Quarter is exactly 17 Days away.
If ADMP holds true to their press release..."recent discussions with our clinical research organization partner suggest that patient enrollment will begin by the middle of next quarter".
They should be announcing the Dosing of the first patient within the next two weeks!
~Can't wait to see this thing really start to take off!
Patient enrollment will begin by middle of 3Q.
Best line in the new investor's presentation:
Follow up on Symjepi international deals
reply from IR: